Posted by Michael Wonder on 28 Sep 2022
Thermo Fisher Scientific announces FDA approval of Oncomine Dx Target Test as the first NGS based companion diagnostic to aid in therapy selection for patients with RET mutations/fusions in thyroid cancers
27 September 2022 - Approval also marks the second NGS based companion diagnostic to identify RET fusion positive locally advanced or metastatic non-small cell lung cancer.
The US FDA has granted approval to Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic to aid in selection of patients with RET fusion positive locally advanced or metastatic non-small-cell lung cancer, RET fusion positive advanced or metastatic thyroid cancer and RET mutation positive advanced or metastatic medullary thyroid cancer who may be eligible for treatment with Lilly’s Retevmo (selpercatinib).
